About this Research Topic
This Research Topic aims to explore the therapeutic potential of TAAR-1 receptor agonists in neuropsychiatric disorders. With the increasing prevalence of mental illnesses worldwide, there is a growing need for innovative treatments that can effectively address the complex and debilitating symptoms associated with these disorders.
This Research Topic aims to provide a comprehensive overview of the current state of research on TAAR-1 receptor agonists, covering various sub-topics related to their pharmacology, mechanisms of action, and therapeutic applications.
Sub-Topics include:
1. Trace Amines in Psychiatric Disorders: the role of trace amines in psychiatric disorders, including their impact on neurochemical pathways and their relevance to the pathophysiology of various mental illnesses.
2. Pharmacology of Trace Amine Receptors: pharmacological aspects of trace amine receptors, focusing on their structure, function, and interactions with TAAR-1 receptor agonists. Insights into the molecular mechanisms underlying the effects of these agonists in neuropsychiatric disorders.
○ Behavioural Pharmacology: This aspect will investigate the behavioral effects of TAAR-1 receptor agonists, including their impact on cognitive function, positive and negative symptoms, and overall disease progression.
○ Mechanistic Actions: This sub-topic will elucidate the specific mechanisms of action through which TAAR-1 receptor agonists exert their therapeutic effects in neuropsychiatric disorders. It will explore their modulation of neurotransmitter systems, receptor signaling pathways, and downstream cellular processes.
3. TAAR-1 Receptor Agonists: the use of TAAR-1 receptor agonists, such as Ulotaront and Ralmitaront, in the treatment of neuropsychiatric disorders. Preclinical and clinical studies assessing their efficacy, safety, and tolerability in reducing symptoms and improving overall outcomes for patients.
4. Pharmacokinetics of Ulotaront: pharmacokinetic properties of Ulotaront, including its absorption, distribution, metabolism, and excretion. It will address key factors influencing its pharmacokinetic profile and its implications for dosing and therapeutic optimization.
5. Other Therapeutic Applications: potential therapeutic applications of TAAR-1 receptor agonists beyond the disorders mentioned above. Examining their efficacy and safety in treating other neuropsychiatric disorders, including Major Depressive Disorder, Narcolepsy, Bipolar Disorder, Psychostimulant Addiction, and ADHD.
Through this Research Topic, we aim to gather original research articles, reviews, and perspectives that provide a comprehensive understanding of the therapeutic potential of TAAR-1 receptor agonists in neuropsychiatric disorders. We encourage researchers in the fields of psychiatry, pharmacology, and neuroscience to contribute their novel findings, critical evaluations, and future perspectives to advance the knowledge and application of these promising agents in clinical practice.
This Research Topic aims to provide a comprehensive overview of the current state of research on TAAR-1 receptor agonists, covering various sub-topics related to their pharmacology, mechanisms of action, and therapeutic applications.
Sub-Topics include:
1. Trace Amines in Psychiatric Disorders: the role of trace amines in psychiatric disorders, including their impact on neurochemical pathways and their relevance to the pathophysiology of various mental illnesses.
2. Pharmacology of Trace Amine Receptors: pharmacological aspects of trace amine receptors, focusing on their structure, function, and interactions with TAAR-1 receptor agonists. Insights into the molecular mechanisms underlying the effects of these agonists in neuropsychiatric disorders.
○ Behavioural Pharmacology: This aspect will investigate the behavioral effects of TAAR-1 receptor agonists, including their impact on cognitive function, positive and negative symptoms, and overall disease progression.
○ Mechanistic Actions: This sub-topic will elucidate the specific mechanisms of action through which TAAR-1 receptor agonists exert their therapeutic effects in neuropsychiatric disorders. It will explore their modulation of neurotransmitter systems, receptor signaling pathways, and downstream cellular processes.
3. TAAR-1 Receptor Agonists: the use of TAAR-1 receptor agonists, such as Ulotaront and Ralmitaront, in the treatment of neuropsychiatric disorders. Preclinical and clinical studies assessing their efficacy, safety, and tolerability in reducing symptoms and improving overall outcomes for patients.
4. Pharmacokinetics of Ulotaront: pharmacokinetic properties of Ulotaront, including its absorption, distribution, metabolism, and excretion. It will address key factors influencing its pharmacokinetic profile and its implications for dosing and therapeutic optimization.
5. Other Therapeutic Applications: potential therapeutic applications of TAAR-1 receptor agonists beyond the disorders mentioned above. Examining their efficacy and safety in treating other neuropsychiatric disorders, including Major Depressive Disorder, Narcolepsy, Bipolar Disorder, Psychostimulant Addiction, and ADHD.
Through this Research Topic, we aim to gather original research articles, reviews, and perspectives that provide a comprehensive understanding of the therapeutic potential of TAAR-1 receptor agonists in neuropsychiatric disorders. We encourage researchers in the fields of psychiatry, pharmacology, and neuroscience to contribute their novel findings, critical evaluations, and future perspectives to advance the knowledge and application of these promising agents in clinical practice.
Keywords: TAAR-1 receptor, antagonists, schizophrenia
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
